Recent Advances in Nanocarrier Systems for the Co-Delivery of siRNA and Chemotherapeutic Drug for Breast Cancer Therapy

Breast cancer's heterogeneity demands innovative therapies. Co-delivery of therapeutics using nanocarriers, especially siRNA combined with other chemotherapeutic drugs, presents a promising avenue. These systems safeguard siRNA, enhance its cellular uptake, and facilitate simultaneous targeting of multiple oncogenic pathways. This multifaceted approach holds potential for superior efficacy and reduced toxicity, addressing the limitations of conventional treatments and paving the way for improved breast cancer therapy.